AzTrials
AzTrials

Benign Breast DiseaseNCT00259597

Nuclear Morphology of Breast Cells in Ductal Lavage

An observational study of Benign Breast Disease, run by University of Michigan at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Breast nipple aspirate fluids (NAF) are useful for non-invasive monitoring of the breast. NAF has been shown to exhibit large inter-individual differences in lipid peroxidation. Unfortunately, the yield of epithelial cells in NAF is low. More recently, breast ductal lavage has been approved for clinical use. Read more about this study

Who is it for?
Ages 18 years and older, women onlyHealthy volunteers can take part
Conditions the study is for
Benign Breast Disease
What is being tested?
breast ductal lavage
Type of treatment
Surgery or procedure
How many people
57 participants
Where
1 siteUnited States
Study dates
Jun 2004to Jun 2007
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: women with a previous biopsy of proliferative breast disease

Who may be able to join

  • Age 18 and older
  • A diagnosis of proliferative breast disease
  • At least 1 month post biopsy
  • At least 3 months post any therapy such as tamoxifen
  • Good general health
  • Sign Consent Form.

Who cannot join

  • Pregnant or lactating (lactation must have stopped at least 3 months prior)
  • Taking coumadin
  • Any diseases including cardiovascular, high blood pressure and diabetes

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Karmanos Cancer Institute

    Detroit, Michigan, 48201

Other trials in United States

About this study

Official title: Morphometry of Breast Cells in Ductal Lavage

Breast nipple aspirate fluids (NAF) are useful for non-invasive monitoring of the breast. NAF has been shown to exhibit large inter-individual differences in lipid peroxidation. Unfortunately, the yield of epithelial cells in NAF is low. More recently, breast ductal lavage has been approved for clinical use. Nuclear morphologic features of breast biopsies have been shown previously to have prognostic value for breast cancer risk. In women without cancer, there may be subtle changes in the breast epithelial cells that can only be defined with computer-assisted measurements. The subjects selected for this study will be 98 women with biopsy-confirmed proliferative breast disease. These women are at slightly increased breast cancer risk, and exhibit higher mean levels of cholesterol and cholesterol oxides in NAF than women with non-proliferative histology in the breast. Levels of 8-isoprostane, cholesterol, fatty acids, fat-soluble micronutrients and 2,6-cyclolycopene-4,5-diol will be quantified in breast NAF that is obtained before breast lavage. These measures were chosen based on their potential relationship to dietary intakes and to oxidative stress, which is relevant to the application of these methods to dietary prevention studies.The investigators will characterize the morphology of breast epithelial cells from lavage using quantitative image cytometry to capture nuclear and cellular area, diameter, roundness, perimeter, and nuclear:cytoplasmic area ratio. Correlations will be evaluated between the measured morphologic features and each analyte in the NAF. The impact of various clinical, demographic and dietary factors on cellular morphology will also be explored. This study will help establish the feasibility of using these measures as endpoints in dietary intervention studies and will generate hypotheses that should be tested in larger studies. Such measures also should be applicable to molecular epidemiological investigations that seek to examine the impact of certain gene polymorphisms and environmental exposures on biomarkers of cancer risk.

Read the detailed description

WHY THE STUDY IS BEING DONE

Breast nipple aspirate fluids (NAF) can be obtained non-invasively from women, making analyses of this fluid relevant to studies of breast cancer risk. The inter-individual variation for lipid oxidation products (a type of damage to fats) in NAF is more than 100-fold, and these oxidation products are likely to have a toxic effect on the breast epithelial cells. During breast ductal lavage, NAF is first aspirated, and the ducts producing fluid are then subjected to lavage to obtain epithelial cells. The nuclear features (morphology) of these cells can then be examined. Nuclear morphology is a quantitative method to observe subtle changes in nuclear features, and these measures in benign breast biopsies have been shown to have prognostic value for breast cancer risk.

This exploratory study will help establish the feasibility of using these measures as endpoints in dietary intervention studies. Since the differences in lipid oxidation levels in NAF are markedly large, it is reasonable to believe that there must be some influence on nuclear morphology. These measures also should be applicable to investigations that seek to examine the impact of certain genetic polymorphisms and environmental exposures on biomarkers of oxidative stress and breast cancer risk.

We will study women who have been diagnosed previously with proliferative breast disease. These women may be good candidates for dietary prevention studies since they are at somewhat increased risk of breast cancer, receive little beyond surgery for treatment, and have been shown to have higher levels of lipid oxidation in the breast than women with no such diagnosis.

WHAT WE HOPE TO ACCOMPLISH

We hope to determine the feasibility of obtaining and analyzing both NAF and breast epithelial cells from women with benign proliferative breast disease. These women are at increased breast cancer risk, and the composition of the NAF, which bathes the breast ducts may affect the morphological features of the nuclei in the breast epithelial cells. If the levels of lipid oxidation products are higher in women with large nuclei (a risk factor for breast cancer), then interventions which reduce oxidative stress and cancer risk may be planned in the future.

The aims are:

  1. To determine if levels of fats, damaged or oxidized fats, oxidized or damaged vitamins and vitamins (8-isoprostane, cholesterol, fatty acids, tocopherols, carotenoids and 2,6-cyclolycopene-4,5-diol) can be quantified in breast NAF obtained before breast lavage. Levels in NAF will be compared to that in blood. These measures were chosen based on their potential relationships to dietary intakes and to oxidative stress levels, which is relevant to intervention studies. Tocopherols and carotenoids are dietary antioxidants, and certain fatty acids are oxidized more readily than others. Both 8-isoprostane and 2,6-cyclolycopene-4,5-diol appear to be markers of oxidative stress.
  2. To obtain breast lavage fluids from women with proliferative breast disease and to characterize the nuclear morphology of breast epithelial cells in the breast lavage fluid. We will quantify various measures commonly used in biopsies including nuclear diameter, circumference, area, roundness and nuclear:cytoplasmic area ratio. These measures have been shown to be related to breast cancer risk. If there are sufficient cells, analysis of oxidative DNA damage will be made using the comet assay.
  3. To examine whether nuclear morphology is associated with levels of oxidative stress in the NAF. Correlations will be evaluated with levels of 8-isoprostane, cholesterol, specific fatty acids, 2,6-cyclolycopene-1,5-diol and fat-soluble micronutrients. The potential influence of diet, demographic factors and nature of previous biopsy diagnosis on nuclear morphology will also be examined as a sub-aim in an effort to better understand differences among women in the nuclear morphology of epithelial cells from ductal lavage.

The materials gathered for research purposes will be:

Consent Form Health Status Questionnaire Food Frequency Questionnaire Height and body weight Breast nipple aspirate fluid Breast lavage fluid 10-ml Blood sample biopsy date, diagnosis and history of medical problems from the medical chart

SAMPLE SIZE

It was desired to equip our study so that the variables of interest can be determined within a coefficient of variation (CV) of 25%, with 90% confidence. Sixty subjects would yield estimates of the mean level of 8 of the 9 study variables to within a CV of 25%, with 90% confidence. The one exception is the highly variable 8-isoprostane measure, whose mean level could be estimated to within a CV of 37%, with 90% confidence.

HOW THE STUDY WILL BE CONDUCTED

A total of 75 women will be recruited for this study over roughly 13 months (ten months of year 1 and 3 months of year 2) by a clinician. She will confirm from the patient chart the previous diagnosis of proliferative breast disease, obtain the type of breast disease diagnosed, how long ago it was diagnosed to the nearest month, and any breast or health problems that could affect the lavage results. The study subjects will fill out questionnaires, be weighed and measured for height, donate a 10-ml blood sample and undergo a breast lavage procedure. During the lavage procedure, breast nipple fluid and the lavage fluid will be collected.

Breast ductal lavage is an important new procedure that can be used to help determine a woman's risk for breast cancer. It is an attractive diagnostic method since it is associated with very little discomfort. At present, it is only used in certain women who are thought to be at very high-risk for breast cancer. During the ductal lavage procedure, the fluid-producing ducts must first be identified. This is done by first freeing the ducts at the nipple surface of keratin plugs, and a woman then uses massage to produce fluid. This fluid, called nipple aspirate fluid (NAF), is what bathes the breast ducts and will be collected for analysis in this proposed project. Once the ducts that produce NAF are identified, the physician then lavages the duct. The lavage fluid washes out breast cells that can then be evaluated by a pathologist to determine whether or not they are normal. The entire procedure is done using anesthetic at the nipple surface initially and in the lavage fluid to minimize any discomfort, and levels of discomfort is generally less than that with a mammogram.

An early indicator of breast cancer risk may be the characteristics of the epithelial cells from the lavage fluid. These breast cells are dislodged upon lavage, they are placed onto a slide and a pathologist examines them for abnormalities. Beyond the pathological diagnosis, there may be subtle changes in the appearance of the cells. Changes in the size and shape of the cell nucleus can be measured using a computer-driven microscope that has quantitative image analysis software. Increases in nuclear area, diameter and perimeter and less uniform roundness of nuclei are known to be associated with breast cancers of higher grade. These kinds of measures have also been measured in breast biopsies that were either normal or hyperplastic, and those women with larger nuclei in completely benign breast biopsies were more likely to develop breast cancer 1-33 years later.

One factor that may affect the shape of nuclei in breast cells is the level of oxidative stress in the breast. The breast fluid is very rich in fats, or lipids, and certain kinds of lipids are easily oxidized. NAF also contains vitamins obtained from fruits and vegetables that function as antioxidants to stop lipid oxidation. For example, carotenoids can react with harmful oxidants to form oxidized carotenoids. We will therefore measure levels of one lipid peroxidation marker and one oxidized carotenoid in NAF as markers of oxidative stress. We also will measure fatty acid levels and levels of un-oxidized carotenoids. We then will determine if differences in the composition of the NAF are related to the measures of nuclear shape made on breast cells.

The breast NAF and blood will be analyzed for cholesterol using spectrophotometric kits. Fatty acids will be analyzed using gas chromatography. Total 8-isoprostanes will be analyzed by immunoassay kits. Micronutrients and vitamins will be analyzed by high pressure liquid chromatography. Nuclear morphology will be analyzed by a computer-driven microscope. DNA damage in breast cells will be analyzed using gel electrophoresis of lysed cells (comet assay). Statistical analyses will allow us to determine if the NAF and blood measures are related to each other and to the nuclear measures.

Being tested
breast ductal lavage
Keywords
nuclear morphology, image analysis, lipid peroxidation, diet, proliferative breast disease
Medical subject headings
Cystic Fibrosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • breast ductal lavageProcedure or surgery

    breast ductal lavage and nipple aspiration done once

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Nov 2005 (estimated)
  2. Study startJun 2004
  3. Primary completionJun 2007
  4. Study completionJun 2007

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
57 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00259597
Sponsor's protocol ID
Morphology
Other IDs
1R21CA100575-01A1
Status last verified
Nov 2008
First submitted
28 Nov 2005
Last updated
20 Dec 2012
Results posted
No
Data monitoring committee
Yes

Publications

  • Djuric Z, Edwards A, Madan S, Darga L, Ren J, Blake C, Koletsky M, Heilbrun LK. Obesity is associated with atypia in breast ductal lavage of women with proliferative breast disease. Cancer Epidemiol. 2009 Oct;33(3-4):242-8. doi: 10.1016/j.canep.2009.07.003. Epub 2009 Jul 28.

    PubMed 19683484

Questions about this trial

What is this clinical trial studying?

An observational study of Benign Breast Disease, run by University of Michigan at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 20 Dec 2012. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00259597, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Dec 2012.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in